Technical analysis of PTC Therapeutics, Inc. (PTCT): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications.
Price Performance
| 1 month | -4.07% |
| 3 months | -12.04% |
| Year-to-date | -19.85% |
| 1 year | -10.38% |
| 3 years | +211.73% |
| 5 years | +46.38% |
| 10 years | +1117.60% |
52-Week Range
| 52-week High | $90.87 |
| 52-week Low | $58.80 |
| Avg Volume (90d) | 1.3M |
Technical Indicators
| SMA 50 | $65.18 |
| SMA 200 | $70.60 |
| Beta | 0.55 |
| 30-day Volatility (annualised) | 43.1% |
| Price vs SMA 50 | -6.6% |
| Price vs SMA 200 | -13.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $75.96 | |
| 2026-01 | $75.53 | -0.6% |
| 2026-02 | $68.19 | -9.7% |
| 2026-03 | $68.13 | -0.1% |
| 2026-04 | $65.06 | -4.5% |
| 2026-05 | $73.85 | +13.5% |
| 2026-06 | $81.57 | +10.5% |
| 2026-07 | $68.01 | -16.6% |
| 2026-08 | $69.54 | +2.2% |
| 2026-09 | $64.78 | -6.8% |
| 2026-10 | $59.97 | -7.4% |
| 2026-11 | $60.88 | +1.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2027-02-18 | $0.29 | $329M |
| 2026-10-29 | $0.14 | $306M |
| 2026-07-30 | $0.24 | $299M |
| 2026-05-07 | $-0.45 | $217M |
| 2026-02-19 | $-0.21 | $279M |
| 2025-11-04 | $-1.19 | $281M |
| 2025-08-07 | $-1.07 | $191M |
Price
| Price | $68.12 (closing price, November 3, 2026) |
| Market Cap | $5.7B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -29.74 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -3.33 |
| Current Ratio | 3.27 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 1.85 |